Investor Relations

Press Releases

 
Press Releases
  Date Title and Summary View
Nov 3, 2016
- Topline Results Expected in 2017 - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced initiation of a Phase 2 placebo-controlled t...
Oct 24, 2016
- Conference Call Scheduled for Thursday, November 3, 2016 at 4:30pm ET - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that th...
Aug 30, 2016
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the 2016 Wells Fargo Securities Healthcare Conference in Boston, MA. ...
Aug 4, 2016
- Completes Enrollment of Second Cohort of Patients in RT002 Phase 2 Study for Cervical Dystonia - - Updates 2016 Financial Outlook - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin produc...
Jul 21, 2016
- Conference Call Scheduled for Thursday, August 4, 2016 at 4:30pm ET - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the ...
Jul 14, 2016
- Company plans to initiate global Phase 3 program in the second half of 2016 - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced t...
Jul 5, 2016
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Julian S. Gangolli, President, North America, of GW Pharmaceuticals plc, has been elected to Revance's Boa...
Jun 13, 2016
NEWARK, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today reported results from its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel (RT001) to treat patients with moderate to severe later...
Jun 2, 2016
- Portfolio covers diverse and novel indications, compositions and formulations - - Acquisition expands IP rights into inflammation, pain, dermatologic and neurologic disorders- NEWARK, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in ...
May 31, 2016
NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in two upcoming investor conferences. Revance management is scheduled to present at the Jeff...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase
Shareholder Tools